Carregant...
Feasibility and attractiveness of indication value-based pricing in key EU countries
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use...
Guardat en:
| Publicat a: | J Mark Access Health Policy |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Co-Action Publishing
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4864834/ https://ncbi.nlm.nih.gov/pubmed/27226845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v4.30970 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|